Last updated: April 23, 2026
Pindolol: Who Manufactures It and How to Verify Supply Chain Coverage
Which companies supply pindolol (API and/or finished dosage forms)?
The supplier set for pindolol is dominated by generic manufacturers supplying pindolol (API) and branded or generic pindolol tablets across multiple jurisdictions. In practice, supply chain coverage is confirmed through:
- Public API listings (trade directories and supplier catalogs)
- Regulatory product databases that list marketing authorisation holders and manufacturers
- DMF/EDMF-linked filings (where available) and label/manufacturer lines on marketed products
This response provides a structured supplier framework for pindolol, including the categories of suppliers that typically carry the molecule and the exact verification points used to confirm they are active.
What supplier categories matter for pindolol?
Pindolol supply typically breaks into two lanes:
-
API suppliers
Firms that manufacture or distribute pindolol active pharmaceutical ingredient for generic formers.
-
Finished dose suppliers (tablets)
Firms that market pindolol tablets (strengths commonly 5 mg and 10 mg in many markets) with a listed manufacturer of the finished product on the product label/registration.
Which verification points prove a supplier is supplying pindolol?
Use these proof points to validate supplier claims quickly:
| Proof point |
Where it appears |
What to check |
| Strength and dosage form |
Product label, SmPC, or national registration listing |
Confirms the supplier is tied to marketed pindolol tablets |
| Manufacturer name lines |
Labeling, registration dossier metadata |
Distinguishes site vs marketing authorisation holder |
| API name in manufacturing chain |
Regulatory filings, DMF references where public |
Confirms pindolol is actually the API used |
| Batch/COA references |
COA documents from suppliers |
Confirms commercial readiness (lot-level evidence) |
Where do pindolol suppliers show up in regulated listings?
Pindolol is widely distributed as a generic cardiovascular medicine, so supplier visibility is highest in regulatory product databases and label disclosures.
Key jurisdictions and databases to map suppliers
| Jurisdiction |
Database |
Supplier info you can extract |
| US |
FDA Orange Book |
ANDA holders and branded/generic label/manufacturer details |
| EU/EEA |
National competent authority product databases and EMA-linked resources |
MAH, manufacturing sites, presentation strengths |
| UK |
MHRA product and medicines listings |
Marketing and manufacturing details reflected in listings |
| Canada |
Health Canada drug product database |
Market authorization and manufacturing/label data |
| Global |
Trade and supplier directories |
Often useful to shortlist, but must be validated against regulatory evidence |
How to build a usable supplier list (API and finished dose) for pindolol
A business-grade supplier list for pindolol usually includes three layers:
-
Tier 1: Finished dose manufacturers (marketed tablets)
- Choose firms with repeated product appearances across multiple strengths/pack sizes.
- Extract the named finished product manufacturer site.
-
Tier 2: API manufacturers
- Choose firms that show pindolol API supply in catalogs plus regulatory linkage (when accessible).
- Extract the listed API manufacturer site.
-
Tier 3: Distributors/packagers
- Identify distributors only after you confirm the actual manufacturer site through COAs, DMF/EDMF references, or label/manufacturing disclosures.
Supplier landscape characteristics for pindolol
Pindolol is not a “single-supplier” market. Supply is fragmented among:
- Generic manufacturers of cardiovascular beta-blockers
- API producers serving multiple beta-blockers and antihypertensive molecules
That means supplier switching is feasible, but quality and compliance must be validated for each site before onboarding.
Key compliance filters for choosing pindolol suppliers
When shortlisting pindolol sources, use these hard filters:
| Filter |
Standard practice |
Why it matters |
| GMP status at the manufacturing site |
Review last inspection outcomes and current GMP standing where available |
Reduces supply interruption risk |
| DMF/EDMF availability (if applicable) |
Confirms regulatory familiarity and submission readiness |
Supports faster regulatory integration |
| Analytical package availability |
CoA, specs, impurities, polymorph control where relevant |
Ensures batch-to-batch consistency |
| Sterility is not relevant (oral solid) |
Tablets generally need GMP for oral solids, not sterile manufacture |
Streamlines onboarding compared with sterile injectables |
Key Takeaways
- Pindolol supply is typically generic-led, with multiple API and finished-dose manufacturers across jurisdictions.
- The fastest reliable path to a supplier list is regulatory listings plus label/manufacturer lines, not catalog claims alone.
- Build procurement readiness by separating API vs finished-dose suppliers, then validating each against site-level manufacturing evidence and lot-level COAs.
FAQs
-
Is pindolol supply dominated by a single supplier?
No. Pindolol is generally supplied by multiple generic manufacturers across API and tablet markets.
-
What is the most reliable way to confirm a supplier actually supplies pindolol tablets?
Confirm the listed manufacturer of the finished product on regulatory product listings or product labels for pindolol strengths.
-
How should companies shortlist pindolol API suppliers?
Shortlist using catalogs, then validate by extracting API manufacturer site evidence from regulatory or dossier-linked documentation.
-
Do pindolol tablets require sterile manufacturing controls?
Typically no, because pindolol is commonly marketed as oral solid tablets, which are non-sterile dosage forms.
-
What documents should be demanded before purchase orders?
Require COA for recent lots, current API/tablet specifications, and proof of GMP compliance for the relevant manufacturing site.
References (APA)
[1] FDA. (n.d.). Drugs@FDA: FDA Orange Book. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ob/
[2] EMA. (n.d.). European Medicines Agency product information and databases. European Medicines Agency. https://www.ema.europa.eu/
[3] MHRA. (n.d.). Medicines and medical devices: product information and databases. Medicines and Healthcare products Regulatory Agency. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
[4] Health Canada. (n.d.). Drug Product Database. Government of Canada. https://health-products.canada.ca/dpd-bdpp/
